Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
Moehler M, Folprecht G, Heinemann V, Holch JW, Maderer A, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Geißler M, Schulz-Abelius A, Linz B, Bernhard H, Paul A, Schmidtmann I, Potthoff K, Schimanski CC. Moehler M, et al. Among authors: overkamp f. Int J Cancer. 2022 Apr 15;150(8):1341-1349. doi: 10.1002/ijc.33881. Epub 2021 Dec 4. Int J Cancer. 2022. PMID: 34807464
Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases.
Schmiegel W, Pox C, Arnold D, Porschen R, Rödel C, Reinacher-Schick A; Association of the Scientific Medical Societies in Germany; German Cancer Aid; German Cancer Society; German Society for Digestive and Metabolic Diseases; German Society for General and Visceral Surgery; German Society for Hematology and Oncology; German Society for Pathology; German Society for Radiooncology; German Roentgen Society; German Joint Society for Clinical Chemistry and Laboratory Medicine; German Society for Coloproctology; Association of Stoma Patients and Persons with Intestinal Cancer; German Crohn's Disease and Ulcerative Colitis Association; German Society for Internal Medicine. Schmiegel W, et al. Dtsch Arztebl Int. 2009 Dec;106(51-52):843-8. doi: 10.3238/arztebl.2009.0843. Epub 2009 Dec 18. Dtsch Arztebl Int. 2009. PMID: 20062582 Free PMC article.
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
Schimanski CC, Möhler M, Schön M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vöhringer M, Heike M, Heinemann V, Peeters M, Kanzler S, Kasper S, Overkamp F, Schröder J, Seehofer D, Kullmann F, Linz B, Schmidtmann I, Smith-Machnow V, Gockel I, Lang H, Galle PR. Schimanski CC, et al. Among authors: overkamp f. BMC Cancer. 2012 Apr 11;12:144. doi: 10.1186/1471-2407-12-144. BMC Cancer. 2012. PMID: 22494623 Free PMC article. Clinical Trial.
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, Loges S. Janning M, et al. Among authors: overkamp f. Int J Cancer. 2019 Aug 1;145(3):857-868. doi: 10.1002/ijc.32163. Epub 2019 Mar 4. Int J Cancer. 2019. PMID: 30694523 Clinical Trial.
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
Schimanski CC, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Heinemann V, Geißler M, Schulz-Abelius A, Bernhard H, Schön MR, Greil R, Galle P, Lang H, Schmidtmann I, Moehler M. Schimanski CC, et al. Among authors: overkamp f. Oncoimmunology. 2020 Aug 23;9(1):1806680. doi: 10.1080/2162402X.2020.1806680. Oncoimmunology. 2020. PMID: 32923171 Free PMC article. Clinical Trial.
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
Huebner H, Kurbacher CM, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, Taran FA, Overkamp F, Tesch H, Häberle L, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Ruebner M, Untch M, Fasching PA, Janni W, Fehm TN, Kolberg HC, Wallwiener D, Brucker SY, Schneeweiss A, Ettl J. Huebner H, et al. Among authors: overkamp f. BMC Cancer. 2020 Nov 11;20(1):1091. doi: 10.1186/s12885-020-07546-1. BMC Cancer. 2020. PMID: 33176725 Free PMC article.
Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients.
Hein A, Gass P, Walter CB, Taran FA, Hartkopf A, Overkamp F, Kolberg HC, Hadji P, Tesch H, Ettl J, Wuerstlein R, Lounsbury D, Lux MP, Lüftner D, Wallwiener M, Müller V, Belleville E, Janni W, Fehm TN, Wallwiener D, Ganslandt T, Ruebner M, Beckmann MW, Schneeweiss A, Fasching PA, Brucker SY. Hein A, et al. Among authors: overkamp f. Breast Cancer Res Treat. 2016 Jul;158(1):59-65. doi: 10.1007/s10549-016-3850-8. Epub 2016 Jun 9. Breast Cancer Res Treat. 2016. PMID: 27283834
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
Fasching PA, Hartkopf AD, Gass P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, Overkamp F, Einarson H, Hadji P, Tesch H, Ettl J, Lüftner D, Wallwiener M, Müller V, Janni W, Fehm TN, Schneeweiss A, Untch M, Pott D, Lux MP, Geyer T, Liedtke C, Seeger H, Wetzig S, Hartmann A, Schulz-Wendtland R, Belleville E, Wallwiener D, Beckmann MW, Brucker SY, Kolberg HC. Fasching PA, et al. Among authors: overkamp f. Breast Cancer Res Treat. 2019 Jan;173(2):319-328. doi: 10.1007/s10549-018-5008-3. Epub 2018 Oct 15. Breast Cancer Res Treat. 2019. PMID: 30324275
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A, Ettl J, Lüftner D, Beckmann MW, Belleville E, Fasching PA, Fehm TN, Geberth M, Häberle L, Hadji P, Hartkopf AD, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg HC, Kurbacher CM, Klein E, Lux MP, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran FA, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker SY. Schneeweiss A, et al. Among authors: overkamp f. Breast. 2020 Dec;54:88-95. doi: 10.1016/j.breast.2020.08.011. Epub 2020 Aug 29. Breast. 2020. PMID: 32956934 Free PMC article. Clinical Trial.
77 results